(Philadelphia, PA) - The main thoroughfare that carries oxygen-rich blood from the heart to the abdomen is known as the abdominal aorta. Strong and thick-walled, this main highway is built to withstand a lifetime of use. But just like expressways traveled by cars and trucks, too much force on its surfaces and exposure to certain environmental factors can cause the vessel to wear and weaken over time - weakening that can lead to abdominal aortic aneurysm (AAA), a bulge in the aorta wall that has a high risk of rupturing.
Risk of AAA is high in smokers, particularly men over age 50, and there is no cure. Long-term survival is poor, especially for patients with large aneurysms and for those who are not able to undergo surgery to prevent eventual rupture.
But now, new research by scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) suggests that AAA can be prevented therapeutically. In work published online May 28 in the journal Cardiovascular Research, they show for the first time in animals that blocking a molecule known as dynamin-related protein 1 (Drp1) can stop AAA from developing.
"While the molecular mechanism of AAA has been unknown, we suspected a connection with mitochondria, which supply cells with energy," explained Satoru Eguchi, MD, PhD, FAHA, Professor of Physiology and Professor in the Cardiovascular Research Center, Sol Sherry Thrombosis Research Center, and Center for Metabolic Disease Research at LKSOM. "We were interested especially in how processes called mitochondrial fission and fusion impact AAA."
Fission and fusion are normal processes by which mitochondria divide and recombine to maintain their function. But blood vessel inflammation, which can be caused by smoking, aging, and other factors, causes mitochondria to shift toward fission. This harmful fragmentation process, which is regulated by Drp1, severely compromises the integrity of the aortic thoroughfare - like the subsurface of an expressway crumbling.
Dr. Eguchi and colleagues, including Hannah A. Cooper, an MD, PhD student in Dr. Eguchi's laboratory at the Cardiovascular Research Center and lead author on the new paper, and collaborators at Okayama University in Japan, observed elevated Drp1 levels in the abdominal aortas of human patients with AAA. They also observed similar Drp1 increases in AAA tissues from mice engineered to develop the condition.
To investigate the significance of elevated Drp1, the researchers treated AAA mice with a compound called mdivi1, which acts as a Drp1 inhibitor. Mdivi1 turned out to attenuate AAA development, based on measurement of the diameter of the abdominal aorta and on molecular study of vascular smooth muscle cells. While treated mice still had high blood pressure associated with their condition, mdivi1 completely protected them against aortic rupture.
Drp1 inhibition was further associated with reduced stress responses in vascular cells. These responses included reduced infiltration of inflammatory cells and decreased senescence, which is characterized by aging-related cellular deterioration.
Dr. Eguchi thinks senescence may be a driving factor behind AAA. Mitochondrial fragmentation accompanied by decreased mitochondrial function and accelerated vascular aging set the stage for increased premature senescence and senescence-associated secretory phenotype (SASP), an aging-related chronic inflammatory condition.
"Human patients and animals with AAA appear young on the outside, but their vascular systems typically show significant aging," Dr. Eguchi said. "Maintaining the mitochondrial fission-fusion balance appears to be fundamental to attenuating senescence and having healthy cardiovascular function. A Drp1 inhibitor may be the therapeutic answer to achieving this goal for persons at risk of AAA."
In future work, Dr. Eguchi and colleagues plan to more deeply explore the mechanisms involved in Drp1-mediated mitochondrial fission and fusion and how they tie into AAA and other cardiovascular diseases.
Other researchers who contributed to the new study include Stephanie Cicalese, Kyle J. Preston, Tatsuo Kawai, Keisuke Okuno, Rosario Scalia, and Victor Rizzo at the Cardiovascular Research Center at LKSOM; Eric T. Choi, MD, FACS, Professor of Surgery and Chair for the Clinical Research Committee of the Center for Metabolic Disease Research at LKSOM, Chief of Vascular and Endovascular Surgery at Temple University Hospital, and Co-Surgical Director of the Temple Heart & Vascular Institute; and Shingo Kasahara, Haruhito A. Uchida, and Nozomu Otaka at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Okayama City, Japan.
The research was supported in part by National Institutes of Health grants RO1HL128324, RO1HL133248, and RO1DK111042.
About Temple Health
Temple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS's physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.
It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.